---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-036294"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T10:44:52.337077+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Femasys Q2 2024 revenue down 31% YoY to $221K; net loss widens to $4.7M

## Summary
- Q2 2024 sales of $221,484, down 31% from $320,514 in Q2 2023.
- Net loss of $4.68M ($0.21 per share) compared to $2.89M ($0.22 per share) a year ago.
- Cash and cash equivalents $13.5M; expects to fund operations into July 2025.
- Received CE Mark for four women's health products; completed U.S. commercial team build-out.

## SEC filing metadata
- accession: 0001140361-24-036294
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036124036294/0001140361-24-036294-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036124036294/ef20033802_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-036294
- JSON: https://secwatch.observer/filing/0001140361-24-036294.json
- Plain text: https://secwatch.observer/filing/0001140361-24-036294.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.